Arc Universities

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

Read more

 

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection.

 

Tags:

Oxford to Cambridge Region to attend UK Real Estate Investment Infrastructure Forum
UKREiiF - 21-23 May 2024
Cambridge and Oxford team up to solve Anglo-Saxon coin mystery
Medieval money mystery solved
Another successful year for Cambridge Enterprise
Another successful year for the University of Cambridge’s innovation arm
Proposals for green energy innovation centre at ARU Peterborough presented at Parliamentary event
Sustainable energy institute plans for ARU Peterborough
Meet Dr Thomas Hambley, ARU’s new Postdoctoral Research Fellow focusing on regional collaboration
ARU appoints new Postdoctoral Research Fellow focusing on regional collaboration for sustainability and environment
University of Bedfordshire renews business innovation and growth partnership with Central Bedfordshire Council
Bedfordshire launches executive development course to boost SME business performance
New course for SMEs supporting business growth
New Begbroke Innovation District to bring research and community facilities to Oxford
Begbroke Innovation District - a living lab for sustainable development
University of Oxford leading the fight against antibiotic resistance
University of Oxford helps to find transformative solutions to antibiotic resistance
Oxford Brookes awarded three prizes at national sustainability awards
Oxford Brookes University wins national sustainability awards